tiprankstipranks
Damora Therapeutics, Inc. (DMRA)
NASDAQ:DMRA
US Market
Want to see DMRA full AI Analyst Report?

Damora Therapeutics (DMRA) Stock Forecast & Price Target

338 Followers
See the Price Targets and Ratings of:

DMRA Analyst Ratings

Strong Buy
8Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Damora
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

DMRA Stock 12 Month Forecast

Average Price Target

$44.43
▲(54.16% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Damora Therapeutics in the last 3 months. The average price target is $44.43 with a high forecast of $51.00 and a low forecast of $40.00. The average price target represents a 54.16% change from the last price of $28.82.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","27":"$27","52":"$52","14.5":"$14.5","39.5":"$39.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$51.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44.42857142857142,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$44.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,14.5,27,39.5,52],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.99,30.68307692307692,32.37615384615385,34.06923076923077,35.762307692307694,37.45538461538462,39.14846153846154,40.84153846153846,42.534615384615385,44.22769230769231,45.92076923076923,47.613846153846154,49.30692307692308,{"y":51,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.99,30.177582417582414,31.365164835164833,32.55274725274725,33.740329670329665,34.927912087912084,36.1154945054945,37.303076923076915,38.490659340659334,39.678241758241754,40.86582417582417,42.05340659340659,43.240989010989004,{"y":44.42857142857142,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.99,29.836923076923075,30.68384615384615,31.53076923076923,32.37769230769231,33.22461538461538,34.07153846153846,34.918461538461536,35.76538461538461,36.612307692307695,37.45923076923077,38.30615384615385,39.153076923076924,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.2,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.77,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.01,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.36,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.05,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.08,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.36,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.85,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.09,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.99,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$51.00Average Price Target$44.43Lowest Price Target$40.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on DMRA
LifeSci Capital
LifeSci Capital
$45
Buy
56.14%
Upside
Reiterated
08/06/26
Sam Slutsky Reiterates Buy Rating on Damora Therapeutics, Maintains $45 Price Target on Promising DMR-001 Profile
Wedbush
$40
Buy
38.79%
Upside
Reiterated
08/06/26
Wedbush Keeps Their Buy Rating on Damora Therapeutics (DMRA)
H.C. Wainwright Analyst forecast on DMRA
H.C. Wainwright
H.C. Wainwright
$45
Buy
56.14%
Upside
Reiterated
08/05/26
Analysts' Top Healthcare Picks: BioCryst (BCRX), Damora Therapeutics (DMRA)
Jefferies Analyst forecast on DMRA
Jefferies
Jefferies
$50
Buy
73.49%
Upside
Initiated
07/26/26
Damora Therapeutics: Buy Rating Reaffirmed on Differentiated ET/MF Candidate and $50 Price Target
RBC Capital Analyst forecast on DMRA
RBC Capital
RBC Capital
$40
Buy
38.79%
Upside
Reiterated
06/30/26
RBC Capital Keeps Their Buy Rating on Damora Therapeutics (DMRA)
Guggenheim Analyst forecast on DMRA
Guggenheim
Guggenheim
$40
Buy
38.79%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), Rhythm Pharmaceuticals (NASDAQ: RYTM) and Damora Therapeutics (NASDAQ: DMRA)
TD Cowen Analyst forecast on DMRA
TD Cowen
TD Cowen
Buy
Reiterated
06/11/26
Analysts' Top Healthcare Picks: Enliven Therapeutics (ELVN), Invivyd (IVVD)
Leerink Partners Analyst forecast on DMRA
Leerink Partners
Leerink Partners
$55$51
Buy
76.96%
Upside
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Damora Therapeutics (NASDAQ: DMRA), Cormedix (NASDAQ: CRMD) and AnaptysBio (NASDAQ: ANAB)
Evercore ISI
$46
Buy
59.61%
Upside
Initiated
03/25/26
Damora Therapeutics initiated with an Outperform at Evercore ISIDamora Therapeutics initiated with an Outperform at Evercore ISI
UBS
$45
Buy
56.14%
Upside
Initiated
02/17/26
Galecto initiated with a Buy at UBSGalecto initiated with a Buy at UBS
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on DMRA
LifeSci Capital
LifeSci Capital
$45
Buy
56.14%
Upside
Reiterated
08/06/26
Sam Slutsky Reiterates Buy Rating on Damora Therapeutics, Maintains $45 Price Target on Promising DMR-001 Profile
Wedbush
$40
Buy
38.79%
Upside
Reiterated
08/06/26
Wedbush Keeps Their Buy Rating on Damora Therapeutics (DMRA)
H.C. Wainwright Analyst forecast on DMRA
H.C. Wainwright
H.C. Wainwright
$45
Buy
56.14%
Upside
Reiterated
08/05/26
Analysts' Top Healthcare Picks: BioCryst (BCRX), Damora Therapeutics (DMRA)
Jefferies Analyst forecast on DMRA
Jefferies
Jefferies
$50
Buy
73.49%
Upside
Initiated
07/26/26
Damora Therapeutics: Buy Rating Reaffirmed on Differentiated ET/MF Candidate and $50 Price Target
RBC Capital Analyst forecast on DMRA
RBC Capital
RBC Capital
$40
Buy
38.79%
Upside
Reiterated
06/30/26
RBC Capital Keeps Their Buy Rating on Damora Therapeutics (DMRA)
Guggenheim Analyst forecast on DMRA
Guggenheim
Guggenheim
$40
Buy
38.79%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), Rhythm Pharmaceuticals (NASDAQ: RYTM) and Damora Therapeutics (NASDAQ: DMRA)
TD Cowen Analyst forecast on DMRA
TD Cowen
TD Cowen
Buy
Reiterated
06/11/26
Analysts' Top Healthcare Picks: Enliven Therapeutics (ELVN), Invivyd (IVVD)
Leerink Partners Analyst forecast on DMRA
Leerink Partners
Leerink Partners
$55$51
Buy
76.96%
Upside
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Damora Therapeutics (NASDAQ: DMRA), Cormedix (NASDAQ: CRMD) and AnaptysBio (NASDAQ: ANAB)
Evercore ISI
$46
Buy
59.61%
Upside
Initiated
03/25/26
Damora Therapeutics initiated with an Outperform at Evercore ISIDamora Therapeutics initiated with an Outperform at Evercore ISI
UBS
$45
Buy
56.14%
Upside
Initiated
02/17/26
Galecto initiated with a Buy at UBSGalecto initiated with a Buy at UBS
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Damora Therapeutics

3 Months
Success Rate
3/3 ratings generated profit
100%
Average Return
+22.63%
Copying David Nierengarten's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +22.63% per trade.
1 Year
Bradley CaninoGuggenheim
Success Rate
5/5 ratings generated profit
100%
Average Return
+32.12%
Copying Bradley Canino's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +32.12% per trade.
2 Years
Bradley CaninoGuggenheim
Success Rate
5/5 ratings generated profit
100%
Average Return
+32.12%
Copying Bradley Canino's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +32.12% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DMRA Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
5
8
12
11
8
Buy
3
1
3
5
6
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
9
15
16
14
In the current month, DMRA has received 14 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. DMRA average Analyst price target in the past 3 months is 44.43.
Each month's total comprises the sum of three months' worth of ratings.

DMRA Financial Forecast

DMRA Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.
No data currently available

DMRA Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

DMRA Stock Forecast FAQ

What is DMRA’s average 12-month price target, according to analysts?
Based on analyst ratings, Damora Therapeutics, Inc.’s 12-month average price target is 44.43.
    What is DMRA’s upside potential, based on the analysts’ average price target?
    Damora Therapeutics, Inc. has 54.16% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is DMRA a Buy, Sell or Hold?
          Damora Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Damora Therapeutics, Inc.’s price target?
            The average price target for Damora Therapeutics, Inc. is 44.43. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $51.00 ,the lowest forecast is $40.00. The average price target represents 54.16% Increase from the current price of $28.82.
              What do analysts say about Damora Therapeutics, Inc.?
              Damora Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of DMRA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.